MedWatch

Bioinnovation Institute ramps up ambitions, wants twice as many companies under its wing

In just four years since the life science incubator was founded, the Bioinnovation Institute's ambitions have only grown. The goal is to double the number of companies under one of the institute's programs, says CEO Jens Nielsen.

The Bioinnovation Institute has set many goals for the next 2-3 years, one of which is to double the number of companies in its portfolio at any given time | Photo: Bioinnovation Institute / PR

Having recently reached a DKK 1bn (USD 153m) milestone, life science incubator Bioinnovation Institute's (BII) ambitions reach new heights.

Since its founding in 2018, when the Novo Nordisk Foundation gave BII an initial grant of DKK 392m (USD 60m), a total of 79 start-ups have gone through or are currently in one of BII's programs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs